CONFIDENTIAL tissue on demand for unmet medical

CONFIDENTIAL … tissue on demand for unmet medical needs Methuselah Foundation Webinar June 10, 2009 Private Presentation This report is solely for the use of intended web audience. No part of it may be circulated, quoted, or reproduced for distribution without prior written approval from Organovo Inc.

Methuselah/Organovo Partnership Angel investors $ Seed Funds Investment Pool Return $$$$$ kmurphy@organovo. com 1

Tissue Printing Is the First Automated Tissue Manufacturing Process Initial steps: adherent cells of interest are isolated or differentiated, preferably from an autologous source from patient (bone marrow, adipose tissue) kmurphy@organovo. com 2

Organ printing: Building Organ Modules, by Borrowing from Nature Spherical cell aggregate: the bioink Supporting biocompatible gel: the biopaper

Blood Vessel Contains Several Cell Types and Is Multilayered Fusion

After Printing, Blood Vessels Are Matured in Perfusion Bioreactors For 6 Weeks to Assure Sufficient Strength of Extracellular Matrix 5

Application to Nerve Regeneration How to repair ruptured nerve? Nerve Structure Fascicle End to end repair Limit the stretching of the nerve to 10% www. backpain-guide. com/. . . /10 -1_Nerve_Struct. jpg kmurphy@organovo. com Autologous graft Can create further trauma to the patient: • Donor site morbidity • Aberrant regeneration • Inadequate return of function

A Number of Attractive Commercial Areas Can Benefit Early From Organ Printing Technology Blood Vessels Cartilage Grafts Cardiac Muscle Grafts Nerve Regrowth kmurphy@organovo. com 7

Vascular Health Presents Several Sets Of Large And Growing Opportunities For Medical Innovation Total US Opportunity = $2. 4 B Dialysis access Leg Artery Grafts 100, 000 leg bypass surgeries year currently 100, 000 new patients/year 350, 000 total patients Cardiac bypass 450, 000 cardiac bypass surgeries year currently Source: HRI Global Medical Device Report, 2006 US Renal Data System 2007 Annual Data Report, Company Projections kmurphy@organovo. com 8

We Hear Clearly from Vascular Surgeons that they Want This Product Market Leg Bypass; Dialysis Access Primary Target Vascular Surgeons Secondary Target Nephrologists “The big limit in surgery is the conduit we use – native vein is the best choice, but works poorly; and you face serious wound issues with vein farming. ” - Maine Vascular Surgeon “Harvesting vein is by far the most invasive component of surgery; provide an alternative that works better than plastics, and surgeons will jump on it” -Cedars-Sinai Vascular Surgeon “We have become glorified plumbers. There is a constant need to unblock current arteriovenous access grafts. ” -UCLA Interventional Radiologist kmurphy@organovo. com 9

Organovo Blood Vessel Graft Has The Potential to Become Standard of Care Success rates for current graft options After 1 year After 3 years Leg Vein 81% 69% Synthetic Graft 66% 52% Dialysis Graft 60% 20% • Current grafts rapidly become blocked • Require time and money to keep vessel open • Unmet need for patient and payer • Cost driver for payer to save $10 -12 k per revascularization Rates given for below knee peripheral bypass except for dialysis graft. Source: W. L. Gore Co. kmurphy@organovo. com 10

Organovo Can Be Capital Efficient Like Our Competition and Differentiate on Price and Improved Structure/Performance Blood Vessel Structure Rolled fibroblast sheet Improvement over current grafts Endothelial cells reduce clotting Smooth muscle cells allow elasticity Flat 2 D tissue culture, manually rolled on dowel, 26 weeks* Automated deposition and incubator maturation, 8 weeks $25 k* $7 -8 k Manufacturing Process Price point target Native artery structure Three layers of cells *Source: Cytograft public materials kmurphy@organovo. com 11

The Promise of Stem Cells Can Be Realized With Tissue Printing 100 -200 companies 400 -500 academic labs Stem Cells Blood Vessels Successful Therapies 1 -2 companies Tissue Chondrocyte Grafts Printing Cardiac Muscle Grafts kmurphy@organovo. com 12

3/18/2018 Organovo’s Scientific Advisory Board Brings Together the Expertise Required for Success David Mooney, Ph. D – Harvard University Professor of Bioengineering Cell signaling interactions Gordana Vunjak-Novakovic, Ph. D – Columbia Professor of Biomedical Engineering Cell culture for tissue engineering Glenn Prestwich, Ph. D – University of Utah Professor of Chemistry Biomaterials expertise Four biomedical companies launched Craig Kent, MD – Chief of Surgery, Univ. Wisconsin Vascular Surgeon Former Chairman, Society for Vascular Surgery kmurphy@organovo. com Advisory Board

Dr. Craig Kent is Key Partner for Preclinical Studies • University of Wisconsin, Madison § Chief of Surgery § Former Chairman, Society of Vascular Surgery • Organovo SAB member • NIH-funded preclinical lab, well published Major Projects Underway Vascular Graft Implantation Patient Cell Sourcing kmurphy@organovo. com 14

Organovo Is Actively Expanding Our Collaborations Craig Kent, U Wisconsin Blood Vessels Paolo Macchiarini, Univ. Barcelona • Small Animal Pre. Clin • Patient Cell Sourcing • Collaborative grants • Pre. Clinical and Clinical Trachea, Esophagus Sanjay Nigam, UC • Collaborative grants San Diego • Research tool sales driver Kidney Peiman Hematti, • Collaborative grants Univ. of Wisconsin • Mesenchymal Stem Cells 15

Contact information: Keith Murphy, CEO (310) 729 -9053 kmurphy@organovo. com Website: http: //www. organovo. com kmurphy@organovo. com 16